Stryker (NYSE:SYK) Price Target Lowered to $380.00 at UBS Group

Stryker (NYSE:SYK) had its price target cut by UBS Group from $400.00 to $380.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the medical technology company’s stock. UBS Group’s target price indicates a potential upside of 7.87% from the company’s previous close.

Several other brokerages have also recently issued reports on SYK. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a research report on Tuesday, January 6th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Sanford C. Bernstein boosted their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research note on Friday, January 9th. Finally, Evercore set a $390.00 price objective on shares of Stryker in a research report on Monday, January 5th. Fourteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $427.50.

Stryker Stock Performance

SYK traded up $2.70 during trading on Tuesday, hitting $352.26. 996,090 shares of the stock were exchanged, compared to its average volume of 2,049,828. The firm has a market capitalization of $134.81 billion, a P/E ratio of 41.89, a PEG ratio of 1.97 and a beta of 0.85. Stryker has a 1-year low of $328.23 and a 1-year high of $404.87. The stock has a fifty day moving average price of $365.22 and a two-hundred day moving average price of $367.06. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same period in the previous year, the company posted $4.01 EPS. The company’s quarterly revenue was up 11.4% on a year-over-year basis. As a group, sell-side analysts predict that Stryker will post 13.47 earnings per share for the current year.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Clayton Financial Group LLC bought a new stake in Stryker during the third quarter worth approximately $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the 4th quarter valued at $26,000. Sankala Group LLC acquired a new position in shares of Stryker during the 4th quarter valued at $26,000. United Financial Planning Group LLC bought a new stake in shares of Stryker in the 3rd quarter worth $27,000. Finally, Atlas Capital Advisors Inc. acquired a new stake in shares of Stryker in the fourth quarter valued at $27,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.